U.S. Stocks Finish in the Red as the AI Trade Falters
Inflation remains an issue for the economy and equity markets.
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Fisher Asset Management Ken Fisher | 14,837,126 | $3,927,981,007 | +12% | 1.13% |
| 2. | Marshall Wace LLP Paul Marshall And Ian Wace | 4,559,795 | $1,207,160,127 | +53% | 1.06% |
| 3. | Quantinno Capital Hoon Kim | 2,106,977 | $557,801,192 | +20% | 0.53% |
| 4. | Squarepoint Ops LLC Maxime Fortin (Cio) | 1,524,770 | $403,667,610 | +23% | 0.44% |
| 5. | Yacktman Asset Management Donald Yacktman | 1,261,078 | $333,857,790 | +1% | 3.99% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 1,250 | $257,687.50 | 1,849 | 2025-11-26 | Filing | |
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $284.39 | 13,072 | $3,717,546.08 | 16,994 | 2026-11-12 | Filing | |
| $274.74 | 22,527 | $6,189,067.98 | 25,447 | 2026-09-02 | Filing | |
| $274.74 | 11,070 | $3,041,371.80 | 25,447 | 2026-09-02 | Filing | |
| $263.36 | 15,000 | $3,950,400.00 | 194,451 | 2026-08-17 | Filing | |
| $261.00 | 102,315 | $26,704,215.00 | 275,967 | 2026-08-13 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 133,971,339 | $35,467,572,287 | 1.03% | |
| 2. | 65,497,363 | $17,301,766,484 | 0.9% | |
| 3. | 61,752,701 | $16,523,170,777 | 0.9% | |
| 4. | 31,590,952 | $8,363,388,632 | 5.87% | |
| 5. | 26,316,977 | $6,967,487,920 | 0.85% |
News See All
Jim Cramer's Top 10 Dividend Stocks for Safe, Consistent Returns
From 2000 through 2009, dividends earned S&P 500 investors an annualized 1.8%, according to Hartford Funds. Even with those payments, the index posted a negative total return for the decade.
10 Worst Dow Stocks To Buy According to Analysts
Yahoo Finance reported on November 5 that the Dow Jones Industrial Average tumbled 3.4%, or more than 1,800 points, while the S&P 500 fell 4.4% and the Nasdaq Composite sank 5.5% into correction territory...
10 Best Healthcare and Insurance Stocks To Buy Following the 2026 Democratic Midterm Sweep
Healthcare stocks emerged as some of the clearest beneficiaries of the Democrats' sweeping victory in the November 3 midterm elections, as investors reassessed the outlook for federal healthcare spending...
Pfizer (PFE) Stock Looks Attractive for Income Investors
Pfizer ($PFE) stock looks attractive for income investors because of its well-covered dividend and modest valuation. The drug maker’s shares have o...
Intuitive Surgical Stock (ISRG) Still Looks Worth Its Premium
Intuitive Surgical ($ISRG) stock still looks worth its premium, in my view. The robotic surgery specialist grew Q3 revenue 22%, while hospitals kep...
10 Most Undervalued Dividend Growth Stocks According to Hedge Funds
Dividend-paying stocks can be an important part of a long-term investment portfolio because they let investors earn steady income while also participating in the stock market's growth.
Johnson & Johnson (JNJ) Reports 69% Tumor Response Rate for Prostate Cancer Drug
Johnson & Johnson ($JNJ) has reported promising early results for its experimental prostate cancer pill, JNJ-6143, which has excited the oncology w...
Johnson & Johnson (JNJ) Drugs Lift Guidance, but Is 23 Times Earnings Fair?
Johnson & Johnson (NYSE:JNJ) raised its 2026 forecast earlier this month.
Johnson & Johnson (JNJ): Are Its Medical Device Deals Paying Off?
Johnson & Johnson (NYSE:JNJ) is turning acquired heart technologies into growing sales.
Hedge Fund Resource Center